Professional
Added to YB: 2026-05-08
Pitch date: 2026-05-06
SLP [neutral]
Simulations Plus, Inc.
+0.63%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.
Market Cap
$317.4M
Pitch Price
$15.96
Price Target
N/A
Dividend
N/A
EV/EBITDA
19.03
P/E
-5.04
EV/Sales
3.43
Sector
Health Care Technology
Category
N/A
Pernas Research Passes On: Simulations Plus, Inc.
SLP (pass): Mechanistic drug dev software for pharma (PBPK modeling, liver toxicity via GastroPlus/DILIsym). Sold off on AI fears, but deterministic/regulatory workflows likely durable. Main risk: big pharma internalizing capabilities vs buying software. Unclear how SLP captures AI upside vs just coexisting. $317M mcap, $15.71/share.
Read full article (1 min)